- Meta-analysis of 75 real-world studies found that Abbott's
FreeStyle Libre system is associated with significant reductions in
glycated hemoglobin (HbA1c) at three months1
- Reductions in HbA1c followed a similar pattern in people with
both type 1 and type 2 diabetes and were sustained for up to 24
months1
- Meta-analysis shows that people with type 2 diabetes who use
insulin benefit from the FreeStyle Libre system in the same way as
people with type 1 diabetes in real-world studies1,
showing the need for access to the latest glucose monitoring
technology
ABBOTT
PARK, Ill., April 28,
2022 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced results from a new meta-analysis of 75 real-world,
observational studies demonstrating that its FreeStyle®
Libre system provides significant reductions in glycated hemoglobin
(HbA1c) that are sustained up to 24 months in adults with both type
1 and type 2 diabetes.1 People with type 2 diabetes
who use insulin are often restricted when it comes to access to
continuous glucose monitoring, but both clinical trials and
real-world studies demonstrate significant improvement of glycemic
control. The results were presented today at the Advanced
Technologies & Treatments for Diabetes (ATTD) Congress,
April 27-30, 2022, in Barcelona.
After three months of using the FreeStyle Libre system, HbA1c
levels were reduced by 0.53% in adults with type 1 diabetes (from
8.20% to 7.67%) and 0.45% in adults with type 2 diabetes (from
8.17% to 7.72%). These are clinically significant reductions of
average glucose levels towards the internationally recommended
HbA1c goal of 7% for adults with diabetes. Reductions were
sustained for up to 24 months in those with type 1 diabetes and up
to 12 months in those with type 2 diabetes, reflecting the duration
of the studies available for analysis. Reductions in HbA1c over
time followed a similar pattern for people with type 1 and type 2
diabetes, demonstrating that, in a real-world setting, people with
type 2 diabetes who use insulin benefit from FreeStyle Libre system
in a similar way as people with type 1
diabetes.1
"Many people with type 2 diabetes who use insulin have a very
similar experience to people with type 1 diabetes in terms of the
risk of complications and the need to monitor blood glucose, but
access to sensing technology is rarely equal for both groups," said
Mark Evans MD FRCP, University
Professor of Diabetic Medicine, University of
Cambridge. "Our analysis demonstrates the value of constant
glucose monitoring to support glycemic control in people with
advanced type 2 diabetes who use insulin as we see clinically
meaningful benefits translated to a real-world setting."
Currently, in most European countries, the FreeStyle Libre
system is reimbursed for all people with type 1 diabetes, but
people with type 2 diabetes can only get the product reimbursed if
they meet certain criteria, such as using insulin several times a
day or having poorly controlled HbA1c levels.
HbA1c provides an estimate of average glucose levels over a
period of time and is the standard measurement of glycemic control
for people with diabetes.2 Increased HbA1c is associated
with a greater risk of developing complications related to
diabetes, such as cardiovascular disease.3 The new
meta-analysis found that people with a higher HbA1c at baseline
experienced greater reductions in HbA1c after being initiated on
the FreeStyle Libre system.1
"Our FreeStyle Libre system is the most widely used wearable
glucose monitor with proven clinical and real-world data from more
than 1 million users," said Alexander
Seibold, EMEA medical director for Abbott's diabetes care
business. "It provides people real-time insights into how
their glucose levels are affected by their daily routines,
empowering them to make healthy adjustments and see the benefit to
their health and life. It puts people with diabetes in control of
their health."
The FreeStyle Libre glucose monitoring system includes a sensor,
which is applied to the back of the upper arm for up to 14 days and
continuously measures glucose, paired with a reader or compatible
smartphone app4 that display glucose readings. It is the
number one sensor-based glucose monitoring system used in
Europe and worldwide.5
Abbott's FreeStyle Libre portfolio has already changed the lives of
approximately 4 million people across 60 countries6 by
providing breakthrough technology that is accessible and
affordable.7
About Abbott:
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 113,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn
at www.linkedin.com/company/abbott-/, on Facebook
at www.facebook.com/Abbott and on
Twitter @AbbottNews.
Indications and Important Safety Information
FreeStyle Libre 14 day system: Failure to use FreeStyle
Libre 14 day system as instructed in labeling may result in missing
a severe low or high glucose event and/or making a treatment
decision, resulting in injury. If readings do not match symptoms or
expectations, use a fingerstick value from a blood glucose meter
for treatment decisions. Seek medical attention when appropriate or
contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety
info.
FreeStyle Libre 2 system: Failure to use FreeStyle Libre
2 system as instructed in labeling may result in missing a severe
low or high glucose event and/or making a treatment decision,
resulting in injury. If glucose alarms and readings do not match
symptoms or expectations, use a fingerstick value from a blood
glucose meter for treatment decisions. Seek medical attention when
appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us
for safety info.
References
1 Evans M, Welsh Z & Seibold A. Reductions in
HbA1c with flash glucose monitoring are sustained for up to 24
months: a meta analysis of 75 real-world observational studies.
Presented at ATTD 2022
2 World Health Organization. Use of Glycated
Hemoglobin (HbA1C) in the Diagnosis of Diabetes Mellitus:
Abbreviated Report of a WHO Consultation Published. 2011. p. 2,
Glycated hemoglobin (HbA1c) for the diagnosis of diabetes.
Available online at:
https://www.who.int/diabetes/publications/report-hba1c_2011.pdf .
Last accessed April 2022.
3 Sherwani SI, Khan HA, Ekhzaimy, et al. Significance
of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.
Biomarker Insights 2016:11 95–104 doi:
10.4137/BMI.S38440
4 The app is only compatible with certain
mobile devices and operating systems.
5 Data on file, Abbott Diabetes Care. Data
based on the number of users worldwide for the FreeStyle Libre
portfolio compared to the number of users for other leading
personal use, sensor-based glucose monitoring systems.
6 Data on file. Abbott Diabetes Care.
7 Based on a comparison of list prices of the
FreeStyle Libre portfolio versus competitor CGM systems available
worldwide. The actual cost to patients may or may not be lower than
other CGM systems, depending on local reimbursement, if any.
View original
content:https://www.prnewswire.com/news-releases/new-analysis-shows-that-abbotts-freestyle-libre-system-provides-similar-and-sustained-reductions-in-glucose-levels-for-people-with-both-type-1-and-type-2-diabetes-301535132.html
SOURCE Abbott